ZOLGENSMA SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ONASEMNOGENE ABEPARVOVEC

から入手可能:

NOVARTIS PHARMACEUTICALS CANADA INC

ATCコード:

M09AX09

INN（国際名）:

ONASEMNOGENE ABEPARVOVEC

投薬量:

20000000000000VG

医薬品形態:

SOLUTION

構図:

ONASEMNOGENE ABEPARVOVEC 20000000000000VG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

5.5ML AND 8.3ML

処方タイプ:

Prescription

治療領域:

CELLULAR AND GENE THERAPY

製品概要:

Active ingredient group (AIG) number: 0162641001; AHFS:

認証ステータス:

APPROVED

承認日:

2020-12-15

製品の特徴

_ZOLGENSMA_
_®_
_ (onasemnogene abeparvovec) _
_Page 1 of 36 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ZOLGENSMA®
onasemnogene abeparvovec
Solution for intravenous infusion, 2 × 10
13
vector genomes/mL
Other drugs for disorders of the musculo-skeletal system
ATC code: M09AX09
Novartis Pharmaceuticals Canada Inc.
700 Saint-Hubert St., Suite 100
Montreal, Quebec
H2Y 0C1
Date of Initial Authorization:
December 15, 2020
Date of Revision:
March 19, 2024
Submission Control Number: 274469
ZOLGENSMA is a registered trademark
_ _
_ZOLGENSMA_
_®_
_ (onasemnogene abeparvovec) _
_Page 2 of 36 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, General
01/2024
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
03/2023
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
03/2023
7 WARNINGS AND PRECAUTIONS, Hematologic
03/2023
7 WARNINGS AND PRECAUTIONS, Immune
03/2023
7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic
11/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 4
4
DOSAGE